- Stocks
- Healthcare
- NASDAQ: SAGE

Price (delayed)

$46.4

Market cap

$2.73B

P/E Ratio

3.5

Dividend/share

N/A

EPS

$13.26

Enterprise value

$2.23B

Sage Therapeutics is a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain. The Company is pursuing

The company's debt fell by 32% YoY and by 6% QoQ

SAGE's gross margin is up by 8% YoY

SAGE's equity has soared by 161% YoY but it is down by 3.7% from the previous quarter

SAGE's quick ratio has soared by 131% YoY but it is down by 17% QoQ

What are the main financial stats of SAGE

Market
Valuations
Earnings

Shares outstanding

58.81M

Market cap

$2.73B

Enterprise value

$2.23B

Price to earnings (P/E)

3.5

Price to book (P/B)

1.41

Price to sales (P/S)

2.44

EV/EBIT

3.35

EV/EBITDA

3.33

EV/Sales

2.01

Revenue

$1.11B

EBIT

$666.15M

EBITDA

$670.93M

Free cash flow

$708.1M

Per share
Balance sheet
Liquidity

EPS

$13.26

Free cash flow per share

$12.09

Book value per share

$32.99

Revenue per share

$19.02

TBVPS

$34.4

Total assets

$2.02B

Total liabilities

$85.96M

Debt

$21.32M

Equity

$1.93B

Working capital

$1.92B

Debt to equity

0.01

Current ratio

27.66

Quick ratio

27.28

Net debt/EBITDA

-0.74

Margins
Efficiency
Dividend

EBITDA margin

60.2%

Gross margin

99.9%

Net margin

59.8%

Operating margin

59.4%

Return on assets

38.1%

Return on equity

40%

Return on invested capital

74.6%

Return on capital employed

34.3%

Return on sales

59.8%

Dividend yield

N/A

DPS

N/A

Payout ratio

N/A

How has the Sage Therapeutics stock price performed over time

Intraday

2.43%

1 week

2.68%

1 month

8.56%

1 year

-22.8%

YTD

-46.36%

QTD

-18.32%

How have Sage Therapeutics's revenue and profit performed over time

Revenue

$1.11B

Gross profit

$1.11B

Operating income

$662.29M

Net income

$666.15M

Gross margin

99.9%

Net margin

59.8%

Sage Therapeutics's operating margin has surged by 101% YoY and by 4.8% QoQ

The company's net margin has surged by 101% YoY and by 4.5% QoQ

SAGE's gross margin is up by 8% YoY

Sage Therapeutics's operating income has increased by 4.9% from the previous quarter

What is Sage Therapeutics's growth rate over time

What is Sage Therapeutics stock price valuation

P/E

3.5

P/B

1.41

P/S

2.44

EV/EBIT

3.35

EV/EBITDA

3.33

EV/Sales

2.01

Sage Therapeutics's EPS has increased by 6% from the previous quarter

SAGE's equity has soared by 161% YoY but it is down by 3.7% from the previous quarter

The P/B is 76% less than the 5-year quarterly average of 5.9 and 48% less than the last 4 quarters average of 2.7

SAGE's P/S is 98% below its last 4 quarters average of 116.6

How efficient is Sage Therapeutics business performance

The ROIC has soared by 192% YoY but it has contracted by 22% from the previous quarter

SAGE's ROA has soared by 163% year-on-year but it is down by 13% since the previous quarter

Sage Therapeutics's ROE has soared by 159% YoY but it has decreased by 14% from the previous quarter

Sage Therapeutics's ROS has soared by 101% YoY and by 4.5% from the previous quarter

What is SAGE's dividend

DPS

N/A

Dividend yield

N/A

Payout ratio

N/A

There are no recent dividends present for SAGE.

How did Sage Therapeutics financials performed over time

The total assets has surged by 144% year-on-year but it has declined by 3.1% since the previous quarter

SAGE's quick ratio has soared by 131% YoY but it is down by 17% QoQ

The company's debt is 99% lower than its equity

SAGE's equity has soared by 161% YoY but it is down by 3.7% from the previous quarter

The debt to equity has plunged by 75% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.